4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-051675
Chief Executive Officer sold 25,000 shares at an average $64.61 ($1,615,160)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-09-28 | Option exercise | +25,000 | $16.21 | $405,250 | 315,279 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-09-28 | Sale | −23,200 | $64.58 | $1,498,214 | 292,079 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-09-28 | Sale | −1,800 | $64.97 | $116,946 | 290,279 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2022-09-28 | Option exercise · Stock Option (Right to Buy) | −25,000 | 33,333 | D | ||
| Open-market sales · 25,000 sh · avg $64.61 · $1,615,160 | |||||||
Loading xslF345X03/doc4.xml…